Latest news for Lhyfe (OTC:LHYFF) Stock

Lhyfe SA is engaged in the production of green hydrogen for mobility and industry. The company designs, builds and exploits its green hydrogen production sites, which have the particularity of being directly connected to the various available renewable energy sources. The Group addresses two priority markets, which are among the emitters of greenhouse gases: the heavy mobility sector (trucks, buses, trains and in the long term, maritime and air transport) as well as (ii) the industry sector, among which chemistry (production of ammonia, methanol, etc.), steel production and glass production are priority targets.

Lhyfe SA

Earnings

Earnings Beats

News

JPMorgan Chase Q3 2024 GAAP EPS $4.37 Beats $4.00 Estimate, Managed Net Revenue $43.315B

Fastenal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAST#NASDAQ">FAST</a>) reported quarterly earnings of $0.52 per share which beat the analyst consensus estimate of $0.51 by 1.96 percent. This is unchanged from the same period last year. The company reported quarterly sales of $1.910 billion which beat the analyst consensus estimate of $1.908 billion by 0.11 percent. This is a 3.47 percent increase over sales of $1.846 billion the same period last year.

FAST

Fastenal Q3 2024 GAAP EPS $0.52 Beats $0.51 Estimate, Sales $1.910B Beat $1.908B Estimate

HC Wainwright &amp; Co. analyst Ed Arce reiterates Mirum Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRM#NASDAQ">MIRM</a>) with a Buy and maintains $66 price target.

Price Target

Reiteration

Analyst Ratings

MIRM

HC Wainwright & Co. Reiterates Buy on Mirum Pharmaceuticals, Maintains $66 Price Target

Wells Fargo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) reported quarterly earnings of $1.42 per share which beat the analyst consensus estimate of $1.28 by 10.94 percent. This is a 4.05 percent decrease over earnings of $1.48 per share from the same period last year. The company reported quarterly sales of $20.37 billion which missed the analyst consensus estimate of $20.41 billion by 0.21 percent. This is a 2.35 percent decrease over sales of $20.86 billion the same period last year.

Earnings Misses

Wells Fargo Q3 2024 GAAP EPS $1.42 Beats $1.28 Estimate, Sales $20.37B Miss $20.41B Estimate

Pop icon Justin Bieber has amassed a sizable cryptocurrency portfolio since his foray into the non-fungible token (NFT) arena in 2021.&nbsp;
What happened: A wallet linked to Bieber received over $2 million in Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) from an NFT project named InBetweeners, which he used to <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38797587/heres-how-much-you-wouldve-lost-if-you-bought-a-bored-ape-when-justin-bieber-did">bag blue-chip collectibles</a> like Bored Apes and Mutant Apes.&nbsp;
Bieber&#8217;s wallet continues to retain value, holding around 146.478 Ether as of this writing, worth $353,575 at a per unit price of $2,413.85, as per <a href="https://platform.arkhamintelligence.com/explorer/entity/justin-bieber">data </a>from Arkham Intelligence.
Bieber's Ether stash has remained unchanged this year, meaning his portfolio was worth $335,720 on Dec. 31, 2023, at a market price of $2,291.95.
Consequently, the music sensation has earned a return of $17,854 on Ether this year, equating to 5.3%.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41255580/satoshi-nakamoto-identity-remains-a-mystery-after-hbo-documentary-bronze-statue-celebrates">Satoshi Nakamoto Identity Remains A Mystery After HBO Documentary: Bronze Statue Celebrates Bitcoin Founder&#8217;s Anonymity – &#8216;We Are All Satoshi&#8217;</a>
Why It Matters: While Bieber's cryptocurrency portfolio included other tokens like Apecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">APE</a>), the majority of the exposure was to the second-largest cryptocurrency.&nbsp;
There hasn't been any outward movement of cryptocurrencies from Bieber's wallet in over two years, around the time that he bought the original Bored Ape in early 2022.&nbsp;
The Canadian music sensation belonged to the elite list of celebrities with a large social media following and a sizable cryptocurrency portfolio.
He currently ranks second in terms of holdings among celebrities with over one million followers, trailing former U.S. president Donald Trump.&nbsp;
Price Action: At the time of writing, Ether was exchanging hands at $2,413.85, up 0.34% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>.  
Image by Budiey on Flickr
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41284847/tesla-reveals-two-seater-cybercab-that-drives-itself">Trump Widens Lead Over Harris In Betting Odds On Prediction Markets —Sets A New High On Crypto-Based Polymarket</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Entertainment

Markets

$APE

$ETH

Justin Bieber's 2024 Crypto Returns – Discover How Much The Pop Icon Made On His Ethereum Investment!

HC Wainwright &amp; Co. analyst Ed Arce reiterates Genfit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNFT#NASDAQ">GNFT</a>) with a Buy and maintains $13 price target.

GNFT

HC Wainwright & Co. Reiterates Buy on Genfit, Maintains $13 Price Target

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Sutro Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRO#NASDAQ">STRO</a>) with a Buy and maintains $12 price target.

STRO

HC Wainwright & Co. Reiterates Buy on Sutro Biopharma, Maintains $12 Price Target

Bank of New York Mellon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) reported quarterly earnings of $1.52 per share which beat the analyst consensus estimate of $1.42 by 7.04 percent. This is a 19.69 percent increase over earnings of $1.27 per share from the same period last year. The company reported quarterly sales of $4.650 billion which beat the analyst consensus estimate of $4.542 billion by 2.38 percent. This is a 6.36 percent increase over sales of $4.372 billion the same period last year.

Bank of New York Mellon Q3 2024 Adj. EPS $1.52 Beats $1.42 Estimate, Sales $4.650B Beat $4.542B Estimate

This agreement marks a significant step forward in Phoenix Motor&#39;s strategic efforts to lead the development of next-generation electric and autonomous bus technology.

Phoenix Motor Reveals New Partnership With Bay Area Founders Club To Advance Establishment Of Its Previously Announced AI Development Center In Silicon Valley, California

HC Wainwright &amp; Co. analyst Joseph Pantginis maintains Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Buy and raises the price target from $40 to $77.

CAPR

HC Wainwright & Co. Maintains Buy on Capricor Therapeutics, Raises Price Target to $77

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk said on Thursday that the company will deploy <a href="https://www.benzinga.com/topic/tesla-fsd">autonomous full self-driving (FSD)</a> technology on its Model 3 and Model Y vehicles in Texas and California next year but there are seemingly multiple hurdles on the way before the company&#8217;s driverless vehicles can be deployed on public roads.
What Stands In The Way: The deployment of robotaxis hinges on technological advancement and regulatory approvals. 
While Musk is optimistic that the company&#8217;s FSD can achieve autonomous driving with future software updates, he has previously expressed similar confidence.
As far back as 2019, Musk said that he was confident about Tesla having operational robotaxis by 2020. Several, including the founder of the Dawn Project and anti-FSD crusader Dan O&#8217;Dowd, are now skeptical about the new promises. 
"Tonight Elon Musk said that Tesla drivers would soon be able to sleep at the wheel of unsupervised Full Self-Driving. This is the exact same promise he made in 2019 when he said FSD owners would be able to fall asleep and wake up at their destination by the end of 2020," O&#8217;Dowd said in a statement to <a href="https://pro.benzinga.com/dashboard">Benzinga</a>.
While Tesla operated about 50 robotaxis, including 20 Cybercabs, without drivers on Thursday at the Cybercab unveiling event, they operated only within the Warner Bros. Discovery Inc.&#8217;s movie studio near Los Angeles, O&#8217;Dowd noted.
Tesla&#8217;s FSD requires active driver supervision on public roads.
The Analyst Take: Analysts are optimistic about Tesla&#8217;s Cybercab, praising its design and cost benefits, but they are <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41286875/tesla-analysts-rave-over-cybercabs-design-cost-advantage-but-production-timeline-sp">concerned about its production timeline</a>, which might not begin until 2026-2027.
This delay could challenge investor confidence despite the vehicle's potential to drive revenue. Regulatory challenges and uncertainties also add to the skepticism around its market readiness.
Robotaxi Design May Pose Regulatory Concerns: Tesla <a href="https://www.benzinga.com/news/24/10/41284847/tesla-reveals-two-seater-cybercab-that-drives-itself">unveiled two vehicles on Thursday</a> for autonomous driving- a two-seater Cybercab and a 20-seater Robovan, neither of which has a steering wheel, pedals, or side mirrors.
While the vehicles stand out from an aesthetic standpoint, it would be difficult to receive approvals for deploying them on public roads without steering wheels or pedals given they are mandated by regulators for the sake of passenger safety. 
Tesla&#8217;s FSD has previously been involved in at least two fatal accidents. However, Musk is of the opinion that robotaxis will be safer than human-driven vehicles given that it wouldn&#8217;t be distracted or tired. 
Though General Motors&#8217; Cruise previously planned to build a robotaxi of its own with no pedals called Origin, it <a href="https://www.benzinga.com/news/24/07/39903020/gms-cruise-abandons-pedal-less-origin-autonomous-vehicle-pivots-to-next-generation-chevrolet-bolt-in">scrapped the plan</a> earlier this year and said it would instead focus on using its next generation of Chevrolet Bolt for autonomous driving operations. 
The decision, GM CEO Mary Barra said in July, will address the &#8220;regulatory uncertainty&#8221; around the Origin with its &#8220;unique design&#8221; while also allowing for cutting costs at Cruise. 
Alphabet Inc&#8216;s Waymo is currently the major player offering autonomous rides in select cities across the U.S. Waymo, however, deploys its <a href="https://www.benzinga.com/news/24/08/40455006/alphabets-waymo-introduces-new-hardware-with-sensors-better-armed-against-winters">sensor suite</a> on vehicles equipped with pedals and steering wheels and manufactured by other automakers, such as the Jaguar Land Rover, for use as robotaxis.
Tesla executive Ashok Elluswamy said in April that the company expects fewer regulatory hurdles for Tesla as other companies like Alphabet Inc. subsidiary Waymo have already cleared the path.
Earlier this week, Ark Invest analyst Tasha Keeney also expressed optimism that regulatory hurdles will pose <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41247281/teslas-robotaxi-platform-could-account-for-90-of-ev-giants-enterprise-value-over-th">less hindrance to Tesla&#8217;s robotaxi plans </a>given that 40 states in the U.S. have either approved autonomous vehicles explicitly or not prohibited them. 
However, the absence of mandated parts on the vehicle might pose an issue. Though Tesla unveiled the Cybertruck without a side view mirror in 2019, the vehicle now has them upon delivery, as regulations mandate it. 
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41286876/goldman-sachs-researchers-see-battery-prices-falling-by-nearly-50-by-2026-end-drivi">Goldman Sachs Researchers See Battery Prices Falling By Nearly 50% By 2026 End, Driving Consumer-Led EV Adoption</a></li>
</ul>
Photo courtesy: Tesla

Tech

TSLA

Elon Musk's Fully Autonomous Driving Dreams Now Scheduled For 2025, But Regulatory Hurdles Stand In The Way Of Tesla's Robotaxi Rollout

HC Wainwright &amp; Co. analyst Edward White maintains Valneva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VALN#NASDAQ">VALN</a>) with a Buy and lowers the price target from $23 to $20.

VALN

HC Wainwright & Co. Maintains Buy on Valneva, Lowers Price Target to $20

Shares of Aehr Test Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHR#NASDAQ">AEHR</a>) rose sharply in today's pre-market trading after the company reported better-than-expected <a href="https://www.benzinga.com/news/earnings/24/10/41281995/aehr-test-systems-stock-climbs-after-better-than-expected-q1-results-heres-why">first-quarter financial results</a>.
Aehr Test Systems reported quarterly earnings of 7 cents per share, which beat the analyst consensus estimate of 2 cents. Quarterly revenue of $13.12 million also beat the consensus estimate of $12.17 million, according to data from Benzinga Pro.
Aehr Test Systems shares jumped 13.9% to $15.17 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>NewGenIvf Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) rose 68.4% to $1.0100 in pre-market trading. NIVF TW Opportunities Master Fund II, L.P. disclosed a 9.9% passive stake in NewgenIVF Group Ltd as of Oct. 4.</li>
<li>ZenaTech Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZENA#NASDAQ">ZENA</a>) gained 40.1% to $2.48 in pre-market trading after declining around 5% on Thursday.</li>
<li>Cemtrex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) shares rose 26.4% to $0.5930 in pre-market trading after declining 34% on Thursday.</li>
<li>LuxUrban Hotels Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUXH#NASDAQ">LUXH</a>) shares gained 26.1% to $0.0637 in pre-market trading after dipping 17% on Thursday. LuxUrban Hotels recently filed a prospectus to sell up to 23.63 million shares of common stock.</li>
<li>Jet.AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JTAI#NASDAQ">JTAI</a>) shares surged 24.1% to $0.1014 in pre-market trading. Jet.AI shares fell around 12% on Thursday after the company announced it entered into an agreement with certain institutional investors to purchase approximately 26.6 million shares of common stock in a registered direct offering.</li>
<li>American Lithium Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLI#NASDAQ">AMLI</a>) gained 15% to $0.9086 in pre-market trading after jumping around 18% on Thursday.</li>
<li>Kindly MD, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) shares jumped 13.2% to $1.4500 in pre-market trading after declining around 7% on Thursday.</li>
<li>Burning Rock Biotech Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNR#NASDAQ">BNR</a>) rose 12.3% to $3.67 in pre-market trading. Burning Rock and Dizal secured NMPA approval for NGS-based companion diagnostic for lung cancer in China.</li>
<li>Akanda Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) gained 12% to $1.21 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Gritstone bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTS#NASDAQ">GRTS</a>) shares dipped 14.3% to $0.0532 in pre-market trading. Gritstone Bio shares dipped around 69% on Thursday after the company announced it voluntarily filed for Chapter 11 restructuring.</li>
<li>Lilium N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LILM#NASDAQ">LILM</a>) shares fell 10.5% to $0.6611 in pre-market trading after declining around 5% on Thursday.</li>
<li>Carmell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) fell 8.8% to $0.3490 in today's pre-market trading after dipping more than 10% on Thursday.</li>
<li>Galaxy Payroll Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLXG#NASDAQ">GLXG</a>) fell 8.5% to $9.42 in pre-market trading after gaining 34% on Thursday.</li>
<li>Luokung Technology Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LKCO#NASDAQ">LKCO</a>) shares declined 8.2% to $1.90 in pre-market trading after dipping 21% on Thursday.</li>
<li>Clearmind Medicine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMND#NASDAQ">CMND</a>) shares declined 8.1% to $1.25 in pre-market trading. Clearmind Medicine announced it has received Institutional Review Board approval from one of its clinical sites in the U.S. for part A of its Phase I/IIa clinical trial in the United States for treating patients suffering from alcohol use disorder.</li>
<li>Momentus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTS#NASDAQ">MNTS</a>) shares fell 7.7% to $0.5850 in pre-market trading after dipping 40% on Thursday. Momentus recently announced a deal to provide launch services for NASA.</li>
<li>Innventure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INV#NASDAQ">INV</a>) shares fell 7.3% to $10.60 after gaining around 8% on Thursday.</li>
<li>MicroAlgo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) declined 7% to $0.3484 in pre-market trading after jumping 49% on Thursday.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) fell 5.6% to $225.35 in pre-market trading on brokerage firm Robinhood after the company's robotaxi unveiling event late on Thursday failed to give investors' confidence.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41272079/top-2-health-care-stocks-that-are-ticking-portfolio-bombs">Top 2 Health Care Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>

Pre-Market Outlook

Movers

Trading Ideas

AEHR

AKAN

AMLI

CETX

CMND

CTCX

GLXG

GRTS

JTAI

KDLY

LILM

LKCO

LUXH

MLGO

MNTS

NIVF

ZENA

Why Aehr Test Systems Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket

These data reinforce the clinical importance of LUPKYNIS&reg;&nbsp;(voclosporin), a second generation calcineurin inhibitor (CNI), for the treatment of adults with active lupus nephritis (LN).
This initial analysis of baseline data from 123 patients with biopsy-confirmed LN who are initiating or have initiated treatment with LUPKYNIS within the last 12 months provides a critical foundation for understanding the real-world effectiveness and usage patterns of LUPKYNIS.&nbsp;

AUPH

Aurinia To Present Six Abstracts, Including Five Poster Presentations, At The American Society Of Nephrology Kidney Week 2024 Taking Place In San Diego, October 23-27

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) with a Buy and maintains $28 price target.

MDWD

HC Wainwright & Co. Reiterates Buy on MediWound, Maintains $28 Price Target

The poster entitled, "Potent Antioxidant and Mitochondrial-protectant Effects of ATH434, a Novel Inhibitor of α-Synuclein Aggregation with Moderate Iron-binding Affinity," demonstrates that the neuroprotective and mitochondrial protectant properties of ATH434 include reducing lipid damage in two distinct and disease-relevant neuronal injury models. Additional studies elucidate the inherent antioxidant properties and benefits of ATH434 in cellular energy usage. ATH434's antioxidant properties were distinguished from those of another iron binding agent approved for treating iron overload. The study was run under the direction of Dr. Daniel J. Kosman, Distinguished Professor of Biochemistry at the State University of New York at Buffalo.

Biotech

Health Care

General

Alterity Therapeutics Limited - American Depositary Shares

ATHE

Alterity Therapeutics Announced New Data Related To ATH434 Were Presented At The Society For Neuroscience 2024-Filing

This represents meaningful progress and is consistent with internal expectations despite higher than industry-anticipated cut point changes. Additionally, it is appealing TTY results with CMS.
The Centers for Medicare and Medicaid Services (CMS) issued 2025 Medicare Advantage Star Ratings on October 10, 2024.&nbsp;

Centene Has Approximately 46% Of Its Medicare Advantage Membership Enrolled In Plans Rated 3.5 Stars Or Higher Vs. Approximately 23% Prior Year - Filing

The Company will direct resources towards advancing the development of its clinical program, TIDAL-01, over other preclinical pipeline assets.&nbsp;
Ines Verdon, M.D., Senior Vice President of Clinical Development, is assuming leadership of all clinical activities.&nbsp;Saryah Azmat has been promoted to Chief Operating Officer
&nbsp;
&nbsp;

TSBX

Turnstone Biologics Expects Streamlining Of Operations To Extend Cash Runway Into Q2 Of 2026; Realigns Resources To Focus On Clinical Advancement Of Selected Tumor-Infiltrating Lymphocyte Therapy

UNTY

Unity Bancorp Q3 2024 GAAP EPS $1.07 Beats $0.95 Estimate, Sales $27.659M Beat $26.095M Estimate

Redburn Atlantic analyst Gonzalo Lopez initiates coverage on MercadoLibre (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) with a Buy rating and announces Price Target of $2800.

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

Lhyfe

News

Latest news for Lhyfe (OTC:LHYFF) Stock